Richard Chesworth

Richard (a.k.a. Ches) rejoined TRV as an Entrepreneur-in-Residence in 2023 and is focused on building the next generation of small molecule focused companies. Prior to joining TRV Richard was an independent consultant working with multiple TRV portfolio companies. Richard was previously CSO at Kymera Therapeutics, head of research and preclinical development at Epizyme, as well as having stints at EnVivo (a.k.a. Forum), SurfaceLogix and Pfizer. Richard has contributed to the research and development programs of fourteen clinical drug candidates over his career, so far resulting in two drug approvals. Ches received his DPhil from Oxford University and did post-doctoral research at Columbia University.

Outside of the office, Richard enjoys spending time with his rescue dogs, Daphne and Willis, watching Liverpool as well as racing cars.